Flow Cytometry and Cell Sorting Facility

项目总结-流式细胞术和细胞分选设备 艾布拉姆森癌症中心（ACC）的流式细胞术和细胞分选设备一直在不断地 自1981年以来由NCI癌症中心资助。该基金被公认为全球领先的 流式细胞仪是细胞学和细胞组学领域最大和最全面的学术流式细胞仪之一。 北美的资源。提供全方位的细胞学服务，包括分析型细胞仪， 30个参数，细胞外囊泡的检测和分析，基本和超稀有细胞分选，单细胞 多组学分析，计算细胞学数据分析，永久数据存档，专家咨询，以及 综合教育方案。Jonni摩尔，博士，病理学和实验室医学教授， 免疫学博士，自1990年以来一直领导该设施。她是2020-2022年的总统。 国际细胞计数促进学会（ISAC），一位著名的深度表型分析专家， 细胞外囊泡细胞仪，并在共享资源操作备受尊敬的专家。领导 团队还包括托马斯威廉姆斯，BS，SCYM（ASCP）CM，新的技术总监的业务和 客户服务，拥有超过30年的共享资源领导地位。Derek Jones，PhD，SCYM（ASCP）CM， 新的研究和发展主任，是一个免疫学博士最近被选为ISAC共享 资源新兴领袖。该小组由其他八名全职同等工作人员提供支助，平均 15年的经验。凭借尖端的细胞学技术和仪器，以及广泛的专业知识， ACC成员可以获得完整的实验设计和技术支持，数据分析， 解释。在本报告所述期间，该机制继续大幅增长，反映了 最近扩大了对癌症研究中基于细胞的分析的兴趣。行政协调会成员占255人中的113人 研究人员（44%）在本报告期间（2018年7月1日至2019年6月30日）使用了该设施。的 机构支持多项高影响研究，包括阐明免疫学和临床反应 PD-1阻断导致新的机制见解并引发新的临床试验（Huang et al.，Nat Med，2019; Huang等人，Nature，2017）。该基金的成功可归因于几个因素： 并留住高素质的工作人员（通过为共享资源实验室工作人员创建新的职业发展轨道）; 不断评估和随后购买最先进的仪器;使用卫星 设施，24/7访问，有目的地靠近主要用户群体;实施一个高效的 培训计划;主要的运营IT支持（在线调度、数据的中央存档、站点许可 研究人员在其实验室进行数据分析的软件）。这导致了高成本效益的 该业务为ACC研究人员提供了世界一流的细胞学专业知识。

PROJECT SUMMARY – Flow Cytometry and Cell Sorting Facility The Flow Cytometry and Cell Sorting Facility at the Abramson Cancer Center (ACC) has been continuously funded by the NCI Cancer Center Support Grant since 1981. The Facility is recognized as a worldwide leader in cytometry and cytomics and is one of the largest and most comprehensive academic flow cytometry Shared Resources in North America. A full range of cytomic services is offered including analytical cytometry of up to 30 parameters, detection and analysis of extracellular vesicles, basic and ultra-rare cell sorting, single cell multiomic analysis, computational cytomic data analysis, permanent data archive, expert consultation, and a comprehensive education program. Jonni Moore, PhD, Professor of Pathology and Laboratory Medicine with a doctorate in immunology, has directed the Facility since 1990. She is the 2020-2022 President of the International Society for the Advancement of Cytometry (ISAC), a noted expert in deep phenotyping and extracellular vesicle cytometry, and a highly respected expert in Shared Resource operation. The leadership team also includes Thomas Williams, BS, SCYM(ASCP)CM, the new Technical Director of Operations and Client Services, with more than 30 years of Shared Resource leadership. Derek Jones, PhD, SCYM(ASCP)CM, the new Director for Research and Development, is an immunology PhD recently selected as an ISAC Shared Resource Emerging Leader. This team is supported by eight other full time-equivalent staff with an average of 15 years' experience. With cutting-edge cytomic technology and instrumentation, and extensive expertise, ACC members have access to complete experimental design and technical support, data analysis and interpretation. During the current period, the Facility continued to experience significant growth, reflecting the recent expanded interest in cell-based analysis in cancer research. ACC members accounted for 113 of 255 researchers (44%) who used the Facility during this reporting period (July 1, 2018 through June 30, 2019). The Facility supported multiple high impact studies, including the elucidation of immunological and clinical response to PD-1 blockade leading to novel mechanistic insights and provoking new clinical trials (Huang et al., Nat Med, 2019; Huang et al., Nature, 2017). The success of the Facility can be attributed to several factors: hiring and retaining highly qualified staff (by creating a new career track for Shared Resource laboratory staff); constant evaluation and subsequent purchase of the most cutting-edge instrumentation; the use of satellite facilities, with 24/7 access, purposefully located near major user groups; implementation of a highly effective training program; major operational IT support (on-line scheduling, central archiving of data, site-licensing software to investigators to perform data analysis in their laboratories). This results in a highly cost-effective operation offering ACC investigators access to world class expertise in cytomics.